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Kidney function is inversely associated with coronary artery
calcification in men and women free of cardiovascular disease:
The Framingham Heart Study.
Background. Among patients with end-stage renal disease
(ESRD), the risk of cardiovascular disease is 10 to 20 times
higher than the general population. Adults with ESRD have
increased coronary-artery calcification (CAC) detected by
electron-beam computed tomography (EBCT). Because the
risk of coronary heart disease is increased even at moderate de-
clines in kidney function, we sought to test whether high CAC
scores are seen among those with mild reductions in kidney
function.
Methods. Men and women free of symptomatic cardiovascu-
lar disease underwent EBCT. Coronary calcium was quantified
using the method described by Agatston. Renal function was
estimated by glomerular filtration rate (GFR). Spearman cor-
relation coefficients were used to test the association between
GFR and CAC.
Results. Three hundred nineteen subjects (162 men/157
women), mean age 60, were included. Mean GFR was 86 ± 23
mL/min/1.73 m2 (range 31–169; 10% with GFR <60 mL/min/
1.73m2). The median CAC scores by quartile of GFR were 85.9,
48.1, 7.9, and 2.7. Overall, the unadjusted correlation of GFR
and CAC was−0.28 (P <0.0001). This remained significant after
adjustment for age and sex (−0.11, P < 0.05), and additionally
after adjustment for body mass index (−0.11, P < 0.05), hyper-
tension (−0.11, P < 0.05), or total cholesterol (−0.12, P = 0.04).
A similar correlation was noted after multivariable adjustment
(−0.10, P < 0.08).
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Conclusion. Mild declines in kidney function are associated
with subclinical coronary artery calcification in a sample of
subjects free of clinically apparent cardiovascular disease. This
might help explain the increased risk of cardiovascular disease
among individuals with renal dysfunction. Larger ongoing stud-
ies are needed to better quantify this finding.
Kidney disease increases the risk of coronary mortal-
ity [1] and all-cause mortality [2]. Among patients with
end-stage renal disease (ESRD), the risk of cardiovascu-
lar disease is 10 to 20 times higher than in the general
population [3], and cardiovascular disease accounts for
50% of all deaths in this population [4]. However, this in-
creased risk occurs even at moderate reductions in kidney
function, independently of cardiovascular risk factors [5,
6].
The mechanism of this increased risk of cardiovas-
cular disease in individuals with kidney disease is not
known. Coronary artery calcification (CAC), detected by
electron-beam computed tomography (EBCT), is a sen-
sitive marker for coronary artery disease [7]. There are
significantly increased quantities of CAC in young adults
with ESRD compared with healthy age-matched control
patients [8–10].
Given the association between accelerated CAC in
ESRD patients, one can hypothesize that an increased
risk for CAC might be seen in subjects with mild to moder-
ate kidney dysfunction. The documentation of increased
CAC among individuals with moderate kidney disease
might partially explain the elevated risk of coronary heart
disease in those with kidney disease. Thus, we hypothe-
sized that declining glomerular filtration rate (GFR), a
measure of kidney function, is inversely associated with
CAC as measured by EBCT in the Framingham Heart
Study.
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METHODS
Study sample
The Framingham Heart Study began in 1948 with the
enrollment of 5209 men and women, 28 to 62 years of
age, with subjects undergoing examinations every 2 years
[11, 12]. In 1971, 5124 men and women were enrolled
into the Framingham Offspring Study, which included
the children or spouses of the children of the origi-
nal cohort. Offspring subjects underwent examinations
approximately every 4 years; the design and methodol-
ogy have been previously described [13, 14]. The cur-
rent investigation is composed of 327 subjects from the
Framingham Offspring Study who attended the sixth ex-
amination cycle and participated in a pilot study of EBCT
imaging.
Subjects were selected as previously described [15]. Of
the first 3219 subjects attending the sixth examination
cycle (1995 to 1998), 349 subjects with clinical cardiovas-
cular disease, 357 who did not reside in New England, and
7 who were not between 35 and 84 years of age, were ex-
cluded from sampling. The remaining 2506 subjects were
stratified by sex, age quartile, and Framingham coronary
heart disease (CHD) risk score quintile. Subjects were
randomly sampled from each stratum, and invited to
undergo EBCT. Thirteen percent declined participation;
refusals were handled by randomly selecting another per-
son from that stratum. A total of 327 subjects underwent
EBCT, 319 of which had serum creatinine assessment.
Covariate data were obtained during the seventh cy-
cle of the Framingham Heart Study (1998–2001). Details
regarding the methods of risk factor measurement and
laboratory analysis have been described [16]. Each ex-
amination included a cardiovascular disease assessment
and blood testing. Subjects with fasting glucose level
≥126 mg/dL (7.00 mmol/L), and/or receiving oral hypo-
glycemic or insulin treatment for diabetes were defined as
diabetic. Subjects with a systolic blood pressure ≥140 mm
Hg or diastolic blood pressure ≥90 mm Hg (average of 2
readings taken by the examining physician), or receiving
medication for treatment of hypertension were defined
as hypertensive. Fasting lipid measures included total
and high-density lipoprotein (HDL) cholesterol. Smok-
ing status was defined as smoking 1 or more cigarettes/day
in the year preceding the examination. Body mass index
was defined as weight (kg) divided by the square of height
(m).
GFR and EBCT determination
GFR was estimated using the simplified Modification
of Diet in Renal Disease (MDRD) Study equation [17,
18], defined as GFR = 186.3 × (serum creatinine)−1·154
× age−0·203 × (0.742 for women). Serum creatinine was
Table 1. Baseline characteristics
Study sample
(N = 319)
Age years 60 ± 9
% Male 51
Body mass index kg/m2 28.5 ± 5.4
Total cholesterol mg/dL 202 ± 37
HDL cholesterol mg/dL 51 ± 17
Glomerular filtration rate mL/min/1.73m2 86 ± 23
Current smoking % 11
Hypertension % 45
Diabetes % 17
Values are expressed as mean ± SD unless otherwise indicated.
measured using the modified Jaffe method. Because the
measure of creatinine can vary across different labora-
tories, creatinine was calibrated using a 2-step process.
First, NHANES III creatinine values were calibrated to
the Cleveland Clinic Laboratory, requiring a correction
factor of 0.23 mg/dL [19]. Then, mean creatinine values
from Framingham, by sex-specific age groups (20–39, 40–
59, 60–69, 70+), were aligned with the corresponding cor-
rected NHANES III age-and sex-specific means.
EBCT scans were conducted between 1998 and 1999
(Imatron C-150 XP scanner, GE Medical Systems,
Waukesha, WI, USA) following previously published
protocols [20, 21]. Scans were read preliminarily by a
technologist and over-read by a radiologist (M.E.C.),
blinded to clinical data. CAC scores were calculated using
the method described by Agatston [20]. Reproducibility
was assessed by rereading 20 scans (r = 0.97 for replicate
readings), and image noise was determined by the SD of
pixel numbers in a region of interest within the aorta.
Statistical methods
We calculated Spearman correlations for GFR and
CAC, including unadjusted correlations, adjusted for age
and sex, and adjusted for age, sex, plus 1 additional risk
factor. Finally, we adjusted for age, sex, BMI, current to-
bacco use, diabetes, hypertension, total cholesterol, and
HDL cholesterol. Covariate data were obtained from the
seventh examination cycle. The SAS CORR procedure
was used to perform correlation analyses [22]. A two-
sided P value of < 0.05 was considered statistically signif-
icant. For descriptive purposes, we graphed median and
interquartile range of CAC by quartile of GFR.
RESULTS
EBCT imaging was performed on 327 participants, 319
of whom had creatinine measured. Baseline character-
istics are shown in Table 1. GFR ranged from 31 to
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Fig. 1. CAC scores by GFR quartile. Medians (solid lines) and in-
terquartile ranges (boxes) are presented.
Table 2. Correlation between GFR and CAC score
Study sample
(N = 319)
Unadjusted −0.28a
Adjusted for age and sex −0.11b
Adjusted for age, sex, and risk factors
BMI −0.11b
Current smoker −0.11c
Diabetes −0.10c
Hypertension −0.11b
Total cholesterol −0.12b
HDL cholesterol −0.10c
Adjusted for age, sex, and risk factors −0.10c
aP value ≤ 0.001.
bP ≤ 0.05.
cP ≤ 0.10.
169 mL/min/1.73 m2; 10% of participants had a GFR
<60 mL/min/1.73 m2.
Higher median CAC scores were seen among lower
quartiles of GFR (Fig. 1). Ranges for GFR quartiles
among men were 39 to 72, 73 to 84, 84.4 to 96, and 96.1 to
169 mL/min/1.73 m2, and among women were 31 to 70.1,
70.3 to 79, 80 to 98, and 99 to 166 mL/min/1.73 m2. The
median CAC scores by quartile of GFR were 85.9, 48.1,
7.9, and 2.7. Overall, the unadjusted correlation of GFR
and CAC was −0.28 (P < 0.001) (Table 2). This remained
significant after adjustment for age and sex (−0.11, P <
0.05). After further adjustment for individual risk factors,
the correlations were attenuated, but still significant after
adjustment for body mass index (−0.11, P < 0.05), hyper-
tension (−0.11, P < 0.05), or total cholesterol (−0.12, P =
0.04). A similar correlation was noted after multivariable
adjustment (−0.10, P < 0.08).
DISCUSSION
We have shown that in this cohort of men and women
free of clinically overt cardiovascular disease, GFR is in-
versely associated with CAC. This relation remained true
after adjustment for age and sex, but was attenuated after
multivariable adjustment, suggesting that the association
is at least partially a reflection of the importance of car-
diovascular disease risk factors both in the development
of CAC and kidney disease.
This is the first study to demonstrate an inverse rela-
tion between kidney function and coronary calcification
among individuals unselected for kidney disease. Simi-
lar studies conducted in dialysis patients demonstrated
greater amounts of CAC than healthy age-matched con-
trols [8–10]. The extent of coronary calcification has been
shown to be associated with calcium [10], phosphorous
[10], serum calcium-phosphorous product [8, 9], serum al-
kaline phosphatase [8], serum parathyroid hormone [9],
and duration of ESRD and dialysis [9], suggesting that
metabolic derangements evident in ESRD may be re-
sponsible for the observed increased coronary artery cal-
cification. Further investigation is necessary to determine
whether these metabolic factors could explain the inverse
association seen in our study sample of participants with
mild to moderate kidney disease.
Limitations
Our sample only contained 319 subjects. Although well
represented across strata of age, sex, and cardiovascular
risk, larger samples are necessary to fully elucidate the
relation between GFR and CAC. In addition, the CAC
quantification was conducted 2 to 4 years prior to mea-
suring GFR, and the association between GFR and CAC
may have been altered by progressive changes in kidney
function. Kidney disease was defined by a single crea-
tinine measure. It is not possible to determine whether
subjects who fulfilled outcome criteria did so for at least
a 3-month period. However, misclassification of subjects
would be likely bias our results toward the null. GFR
was estimated by using the simplified MDRD equation.
The MDRD equation has been validated in subjects with
GFR <90 mL/min/1.73 m2; values outside of this range
are extrapolated [23]. However, we were able to increase
the accuracy of the MDRD equation by performing an
indirect calibration to the laboratory that developed the
equation. Our study sample is not nationally representa-
tive, nor is it ethnically diverse. However, the relations of
risk factors to coronary heart disease outcomes observed
in Framingham have recently been validated in 6 ethni-
cally and geographically diverse cohorts, and they were
found to be applicable in other populations [24].
Lastly, our data are consistent with a link between
mildly reduced kidney function and coronary artery
atherosclerosis, but it is uncertain whether CAC scores
among subjects with mild kidney disease reflect intimal
or medial calcification, or a combination of both. There
is substantial evidence for an association of CAC with
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luminally obstructive coronary artery disease [25], and
with histologic evidence of calcification in atherosclerotic
plaques, rather than medial calcification [26]. However,
medial calcification is common among ESRD patients
[27], and may be a major etiologic factor in arterial stiff-
ness, leading to worsening left ventricular hypertrophy
[28, 29]. Among patients with diabetes, medial calcifica-
tion has shown to be associated with increased risk for car-
diovascular events [30]. While medial calcification may
be common in ESRD patients, intimal calcification likely
accompanies this process. An autopsy study of ESRD pa-
tients demonstrated a high prevalence of calcified intimal
plaques [31], and a report looking at coronary calcifica-
tion in 205 hemodialysis patients revealed a direct asso-
ciation between prevalence cardiovascular disease and
CAC score [10]. Further research is necessary to deter-
mine the pathologic basis of coronary calcification among
individuals with moderate kidney disease, and whether
different types of calcification are associated with differ-
ential cardiovascular risk.
Clinical implications
Although it has been shown that kidney disease in-
creases the risk of cardiovascular events [1, 5, 6], the
mechanism of this increased risk is not known. While it
has been suggested that the increased risk may be the re-
sult of shared cardiovascular disease risk factors [32], kid-
ney disease is a strong and independent risk factor for the
development of CVD [1, 5, 6]. Further research is neces-
sary to determine whether metabolic derangements seen
in ESRD can account for the inverse relation between
increased coronary artery calcification and moderately
reduced kidney function. Increased coronary artery cal-
cification among those with moderately reduced kidney
function may help explain the increased risk of cardio-
vascular disease in this population.
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